Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
REMIFENTANIL (REMIFENTANIL HYDROCHLORIDE)
TEVA CANADA LIMITED
N01AH06
REMIFENTANIL
2MG
POWDER FOR SOLUTION
REMIFENTANIL (REMIFENTANIL HYDROCHLORIDE) 2MG
INTRAVENOUS
2ML
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0133098002; AHFS:
MARKETED
2014-06-05
_ _ _ _ _Page 1 of 42_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N REMIFENTANIL FOR INJECTION 1 mg/vial, 2 mg/vial of remifentanil Lyophilized Powder for Injection Sterile Opioid Component to Anesthesia Teva Canada Limited Date of Revision: 30 Novopharm Court January 2, 2019 Toronto, Ontario M1B 2K9 Control Number: 221336 _ _ _ _ _Page 2 of 42_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................................... 3 CONTRAINDICATIONS .............................................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................................. 4 ADVERSE REACTIONS ............................................................................................................. 14 DRUG INTERACTIONS ............................................................................................................. 16 DOSAGE AND ADMINISTRATION ......................................................................................... 17 OVERDOSAGE ........................................................................................................................... 23 ACTION AND CLINICAL PHARMACOLOGY ....................................................................... 24 STORAGE AND STABILITY ..................................................................................................... 28 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................................ 28 PART II: SCIENTIFIC INFORMATION ............................................................................... 29 PHARMACEUTICAL INFORMATION ................................................................................... Přečtěte si celý dokument